Health 8 September 2026 The Observer (Uganda)
Ugandan Scientists Explore mRNA Vaccines to Prevent Cancer Recurrence
Researchers in Uganda have filed patent applications in the US for novel mRNA vaccine technologies designed to train the immune system to recognize and attack cancer cells. The aim is to prevent cancer from returning after treatment by targeting specific molecular features of tumors. Source: https://observer.ug/news/can-a-vaccine-stop-cancer-coming-back
A significant concern for cancer survivors is the potential for their disease to return. Now, a Ugandan biotechnology firm, Dei BioPharma, is pioneering innovative mRNA vaccine technologies with the long-term goal of preventing cancer recurrence.
Seven patent applications, filed in the United States in August, outline experimental mRNA vaccine concepts. These vaccines aim to help the immune system identify unique molecular markers present on cancer cells. The ambition is to create a platform that can train the body’s defenses to recognize and eliminate cancer cells, thereby reducing the likelihood of the disease coming back after initial treatment.
Dr. Matthias Magoola, founder of Dei BioPharma, is leading this effort. The patent filings cover potential targets for various cancers, including certain leukemias, brain cancers, and those associated with RAS and TP53 gene mutations, as well as HPV-driven cancers. The core idea is to identify distinctive features of cancer cells and educate the immune system to attack them.
This approach differs from traditional cancer classification, which often focuses on the location of the tumor (e.g., breast cancer, lung cancer). Instead, the proposed vaccines target specific molecular abnormalities within the tumor, regardless of its origin. This allows for a more personalized approach, potentially matching patients to vaccines based on the molecular profile of their specific cancer.
The technology leverages mRNA, a method made familiar by COVID-19 vaccines. However, adapting mRNA technology for cancer presents unique challenges, as the immune system must learn to differentiate abnormal tumor cells from the patient’s own healthy tissues. The researchers emphasize that these patent filings represent a scientific endeavor and are not yet available treatments for patients. Extensive research, laboratory work, and clinical trials will be necessary before these potential vaccines can be considered for regulatory approval.
This development signifies a notable advancement in cancer research originating from Uganda, contributing to the global interest in novel cancer therapies. While a long road lies ahead from patent application to patient treatment, this work highlights Uganda’s growing role in biotechnological innovation.
Source: The Observer (Uganda)